Oryzon Genomics S.A. (ORYZF)
USD 3.03
(-0.66%)
USD 3.03
(-0.66%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 18.49 Million EUR | -10.75% |
| 2022 | 20.72 Million EUR | 22.8% |
| 2021 | 16.87 Million EUR | 27.04% |
| 2020 | 13.28 Million EUR | -2.81% |
| 2019 | 13.66 Million EUR | 44.92% |
| 2018 | 9.43 Million EUR | 12.69% |
| 2017 | 8.36 Million EUR | -9.73% |
| 2016 | 9.27 Million EUR | 31.87% |
| 2015 | 7.03 Million EUR | 57.82% |
| 2014 | 4.45 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 3.49 Million USD | -32.73% |
| 2024 Q2 | 1387.18 EUR | 2.86% |
| 2024 Q3 | 2.79 Million EUR | -9.9% |
| 2023 Q3 | 4.18 Million EUR | -13.79% |
| 2023 Q2 | 4.85 Million EUR | -2.14% |
| 2023 Q1 | 4.96 Million EUR | -6.29% |
| 2023 FY | 18.49 Million EUR | -10.75% |
| 2023 Q4 | 4.48 Million EUR | 6.98% |
| 2022 Q1 | 1.7 Million EUR | -60.44% |
| 2022 Q2 | 5.24 Million EUR | 208.12% |
| 2022 FY | 20.72 Million EUR | 22.8% |
| 2022 Q3 | 5.01 Million USD | -4.29% |
| 2022 Q4 | 5.29 Million EUR | 5.58% |
| 2021 Q2 | 3.3 Million EUR | -30.6% |
| 2021 FY | 16.87 Million EUR | 27.04% |
| 2021 Q3 | 4.35 Million USD | 31.86% |
| 2021 Q1 | 4.75 Million EUR | 50.87% |
| 2021 Q4 | 4.3 Million USD | -1.21% |
| 2020 Q2 | 3.14 Million EUR | -30.4% |
| 2020 FY | 13.28 Million EUR | -2.81% |
| 2020 Q4 | 3.15 Million EUR | 28.35% |
| 2020 Q3 | 2.45 Million EUR | -21.92% |
| 2020 Q1 | 4.52 Million EUR | 30.09% |
| 2019 Q2 | 3.59 Million EUR | 27.14% |
| 2019 Q1 | 2.82 Million EUR | 20.23% |
| 2019 Q4 | 3.47 Million EUR | -7.61% |
| 2019 FY | 13.66 Million EUR | 44.92% |
| 2019 Q3 | 3.76 Million EUR | 4.59% |
| 2018 FY | 9.43 Million EUR | 12.69% |
| 2018 Q2 | 2.22 Million EUR | -5.24% |
| 2018 Q3 | 2.28 Million EUR | 2.69% |
| 2018 Q4 | 2.35 Million EUR | 2.97% |
| 2018 Q1 | 2.34 Million EUR | 31.29% |
| 2017 Q4 | 1.78 Million EUR | -13.43% |
| 2017 Q2 | 2.22 Million EUR | -2.89% |
| 2017 Q1 | 2.28 Million EUR | -7.46% |
| 2017 FY | 8.36 Million EUR | -9.73% |
| 2017 Q3 | 2.06 Million EUR | -7.05% |
| 2016 Q2 | 2.6 Million EUR | 26.8% |
| 2016 FY | 9.27 Million EUR | 31.87% |
| 2016 Q1 | 2.05 Million EUR | 18.19% |
| 2016 Q4 | 2.47 Million EUR | 6.07% |
| 2016 Q3 | 2.33 Million EUR | -10.59% |
| 2015 Q3 | 1.68 Million EUR | -10.67% |
| 2015 Q4 | 1.74 Million EUR | 3.24% |
| 2015 FY | 7.03 Million EUR | 57.82% |
| 2015 Q1 | 1.71 Million EUR | 0.0% |
| 2015 Q2 | 1.88 Million EUR | 9.94% |
| 2014 FY | 4.45 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bioxytran, Inc. | 3.82 Million USD | -384.199% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 78.686% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -6967.356% |
| SQZ Biotechnologies Company | 85.61 Million USD | 78.396% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -534.28% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 37.41% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 50.351% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -1131.581% |
| Marizyme, Inc. | 19.23 Million USD | 3.86% |
| Genus plc | 147.7 Million USD | 87.477% |
| Pharming Group N.V. | 225.49 Million USD | 91.797% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -802.868% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1278.791% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -121.814% |
| ContraFect Corporation | 56.88 Million USD | 67.486% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -1150.859% |
| IMV Inc. | 37.7 Million USD | 50.948% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -562.894% |
| ONE Bio Corp. | 6.44 Million USD | -187.049% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 78.478% |
| Mesoblast Limited | 5.9 Million USD | -213.404% |
| MultiCell Technologies, Inc. | 567.42 USD | -3259761.655% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 25.158% |
| Genscript Biotech Corporation | 825.34 Million USD | 97.759% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -4648.132% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -603.975% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -276.117% |
| Biomind Labs Inc. | 994.18 Thousand USD | -1760.535% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -951.164% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -175.336% |
| Skye Bioscience, Inc. | 13.54 Million USD | -36.535% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -892.137% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -110.692% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 74088.428% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -319.562% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -266.857% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -15.533% |
| Accustem Sciences Inc. | 3.74 Million USD | -393.728% |
| EV Biologics, Inc. | 531.96 Thousand USD | -3377.148% |
| Q BioMed Inc. | 3.43 Million USD | -438.234% |
| GB Sciences, Inc. | 1.42 Million USD | -1202.146% |
| Alpha Cognition Inc. | 9.7 Million USD | -90.582% |
| CSL Limited | 3.44 Billion USD | 99.464% |
| Agentix Corp. | 1.37 Million USD | -1248.425% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 81.378% |
| Enzolytics Inc. | 2.17 Million USD | -748.683% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 12.71 Million USD | -45.509% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -406.672% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -907.965% |
| argenx SE | 1.53 Billion USD | 98.794% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 67.798% |
| HST Global, Inc. | 140.9 Thousand USD | -13027.174% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -1671.754% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -1544.319% |
| Halberd Corporation | 74.84 Thousand USD | -24614.875% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -669.132% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -443.237% |
| Zenith Capital Corp. | 8.94 Million USD | -106.833% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -1071.181% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -653.349% |
| AVAX Technologies, Inc. | 7.31 Million USD | -153.029% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -10684.919% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -862.937% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -106077.068% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | -649.854% |
| Helix BioMedix, Inc. | 1.97 Million USD | -837.971% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -70.214% |
| Kadimastem Ltd | 2.41 Million USD | -667.479% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 19.49% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -10092.086% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -1285.104% |
| LadRx Corporation | 3.81 Million USD | -385.26% |
| Cell Source, Inc. | 4.32 Million USD | -327.645% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -4351.996% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1902.914% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1902.914% |
| Affymax, Inc. | 39.38 Million USD | 53.036% |
| Mobile Lads Corp. | 554.54 Thousand USD | -3235.541% |
| Itoco Inc. | 919.14 Thousand USD | -1912.43% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -336.416% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -1553.003% |
| International Stem Cell Corporation | 5.27 Million USD | -250.922% |
| CytoDyn Inc. | 18.05 Million USD | -2.432% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -73391.625% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -8304.796% |
| Qrons Inc. | 643.67 Thousand USD | -2773.663% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -1202.804% |
| SYBLEU INC | 160.87 Thousand USD | -11397.742% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -729.512% |
| Rebus Holdings, Inc. | 664 Thousand USD | -2685.709% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -918.384% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -35037.546% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -90826.152% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 48.996% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -1043.208% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -2413.757% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -494.571% |
| Neutra Corp. | 243.82 Thousand USD | -7486.347% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -5.958% |
| PureTech Health plc | 144.59 Million USD | 87.208% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 9.726% |
| IXICO plc | 4.7 Million USD | -292.97% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -110.266% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 84.291% |
| CSL Limited | 3.89 Billion USD | 99.525% |
| Cellectis S.A. | 97.32 Million USD | 80.994% |